We are living through the fastest period of digital growth in human history. New technologies are transforming how we live, work, connect and innovate.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh